The 2026 Gruber Genetics Prize is being awarded to Alan G Hinnebusch, PhD, a Distinguished Investigator at the National Institutes of Health, for his pioneering work that established both the paradigm and the detailed mechanism of translational control that underlies the Integrated Stress Response, a pivotal mechanism whereby eukaryotic cells reprogram protein synthesis under stress.

In a series of forward genetics screens in budding yeast, Hinnebusch identified mutations in the kinase Gcn2, which phosphorylates the key translation initiation factor eIF2, and Gcn4, a key transcription factor that controls genes involved in amino acid biosynthesis.

Hinnebusch demonstrated that the phosphorylation of eIF2 suppresses global protein synthesis and selectively induces the master transcription factor Gcn4. This translational control mechanism is broadly conserved from yeast to humans.

Hinnebusch’s work has led to a greater understanding of how cells respond to stressors such as amino acid starvation and viral infections. Dysregulation of the integrated stress response has been linked to neurodegeneration, metabolic disorders and cancer.

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have discovered that many gut bacteria use a flexible survival strategy to withstand disruptions such as antibiotics and diet changes. Published in the May 19 online issue of Cell Host & Microbe (DOI: 10.1016/j.chom.2026.04.019), the study shows microbes can switch between functional states, rather than relying solely on genetic mutations, to try to survive shifting conditions. The findings shed light on a previously hidden layer of microbiome biology and may help explain why probiotics and fecal microbiota transplantation (FMT) produce inconsistent benefits across individuals.

A large, multi-center study led by Ann & Robert H. Lurie Children’s Hospital of Chicago derived “achievable benchmarks of care” (ABCs) using electronic health record data, which allows pediatric emergency departments across the country to set high yet realistic performance goals. The new benchmarks are based on high achievers – a shift away from relying on peer averages in performance metrics. The study is published in JAMA Network Open.

In the first U.S. randomized placebo-controlled trial of its kind, researchers from Penn State College of Medicine found that smokers who switched from traditional cigarettes to pod-based salt-nicotine e-cigarettes were three times more likely to quit smoking within six weeks and were exposed to lower levels of harmful tobacco-related toxicants.

Doctors should consider treating high cholesterol much earlier and more aggressively than they have in the past, according to a new perspective by Weill Cornell Medicine, NewYork-Presbyterian and Yale School of Medicine investigators. The updated 2026 cholesterol management guidelines from the American College of Cardiology and the American Heart Association encourage doctors to identify risk earlier and intervene before heart attacks and strokes happen. Heart disease remains the leading cause of death in the United States.